Targeted radiation before a donor stem cell transplant for hard-to-treat AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a targeted radiation therapy called 131I-apamistamab given before a donor stem cell transplant for people with AML that has relapsed or not responded to treatment. The goal is to see if this approach can help more people get a successful transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have acute myeloid leukemia (AML) that has come back or hasn't responded well to treatment, with 5% to 20% leukemia cells in your bone marrow.
- Your leukemia cells must have a specific marker called CD45 on their surface (checked by a lab).
- You must be at least 18 years old and not able to handle very high-dose conditioning chemotherapy.
- You must have a matched donor (8/8 HLA match) who is a relative or unrelated volunteer.
- Your kidneys, liver, and heart need to be working fairly well, and you should be able to care for yourself (Karnofsky score of 70 or more).
- You cannot have had a stem cell transplant before, and you cannot have active leukemia in the brain or spinal fluid.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted radiation drug (Astatine-211) given before a donor stem cell transplant for people with high-risk leukemia or certain bone-marrow cancers. The goal is to better control the cancer before the transplant.
This trial tests a new approach: giving a targeted radioactive antibody (attached to a drug that finds CD38 on cancer cells) along with low-dose chemotherapy and targeted radiation to the bone marrow before a donor stem cell transplant. The goal is to prepare the body for the transplant while killing remaining cancer cells more precisely.
This trial tests a new type of radiation therapy called automated total marrow and lymphoid irradiation (TMLI) given before a stem cell transplant. It's designed to treat blood cancers like leukemia and myelodysplastic syndrome by destroying cancer cells and preparing the body to accept donor stem cells.
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
This trial tests an injection of donor-derived immune cells (called RC1012) to lower the chance of AML coming back after an allogeneic stem cell transplant. It is aimed at people at higher risk of relapse once the transplant is completed.
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
Hear when a new Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.